Skip to main content

Table 2 Characteristics of studies included in the meta-analysis

From: The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis

Study All pts TS detection method Chemotherapy regimen Ethnicity TS expression Evaluable for response Disease stage ECOGPS TS high/+ TS low/-
          OR (pts) Total pts OR (pts) Total pts
Bepler et al. [6] 52 RT-PCR pemetrexed + gemcitabine Caucasian 35 35 I-III NR 5 17 7 18
Chang et al. [30] 110 IHC pemetrexed Asian 55 52 advanced or reoccurent 0-4 23 41 4 11
Chen et al. [21] 268 IHC pemetrexed Asian 49 42 IIIB-IV NR 3 20 5 22
Park et.al [22] 98 IHC pemetrexed Asian 98 88 IB,IIIA-IV NR 5 54 5 34
Takezawa et al. [18] 24 IHC pemetrexed + platinum Asian 24 24 IIIB-IV 0-1 1 12 6 12
Wang et al. [19] 38 RT-PCR pemetrexed + platinum Asian 38 38 IIIB-IV 0-1 2 10 11 28
Igawa et al. [31] 104 IHC pemetrexed Asian 54 54 IIIB-IV or reoccurent 0-3 0 23 5 31
Sun et al. [17] 285 IHC pemetrexed Asian 149 149 IIIB-IV 0-1 9 75 21 74
    pemetrexed + platinum Asian 44 44 IIIB-IV 0-1 4 17 13 27
  1. Abbreviations: TS thymidylate synthase, NR no report, IHC immunohistochemistry, RT-PCR real-time reverse transcriptase PCR, NSCLC non-small cell lung cancer, PTS patients.